Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Go back to Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine| (NASDAQ: VOR) | Delayed: 16.30 +0.20 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.10 | 52 Week High | $ | |||
| Open | $16.12 | 52 Week Low | $ | |||
| Day High | $16.67 | P/E | N/A | |||
| Day Low | $15.85 | EPS | $ | |||
| Volume | 344,799 | |||||
